PI Industries Limited has submitted to the Exchange, the financial results for the quarter and nine months December 31, 2025.
PIIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts more than Nifty Midcap 150 and 1.7 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
PI Industries reported a sharp decline in Q3 FY26 standalone revenue at ₹12,696 Mn, down from ₹17,798 Mn in Q3 FY25 (a fall of roughly 29% YoY). Nine-month standalone revenue fell to ₹47,913 Mn from ₹59,230 Mn a year earlier. Standalone profit after tax for the quarter dropped to ₹2,816 Mn (from ₹4,238 Mn) and for nine months to ₹12,370 Mn (from ₹14,807 Mn). On a consolidated basis, Q3 revenue came in at ₹13,757 Mn and PAT at ₹3,113 Mn, with the Pharma segment swinging to a ₹580 Mn profit in Q3 after losses earlier. The board declared an interim dividend of ₹5 per share (500% on face value of ₹1), with a record date of February 23, 2026. The statutory auditor (Price Waterhouse) issued an unqualified limited review report on the results. An exceptional item of ₹206 Mn (standalone loss from new Labour Codes) and ₹1,051 Mn (consolidated gain from write-back of contingent consideration related to the PI Health Sciences acquisition) were recorded.
Sharply lower year-on-year revenue and profits may pressure the stock in the near term, reflecting weakness in the agro-chemicals business. The strong interim dividend and the one-time gain from the acquisition-related settlement offer some comfort, but the declining topline is a key concern for shareholders.